Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKanabo Grp Plc Regulatory News (KNB)

Share Price Information for Kanabo Grp Plc (KNB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.60
Bid: 1.50
Ask: 1.70
Change: 0.00 (0.00%)
Spread: 0.20 (13.333%)
Open: 1.60
High: 1.60
Low: 1.60
Prev. Close: 1.60
KNB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Materia Malta First Sales in Europe

16 Dec 2021 07:05

RNS Number : 7843V
Kanabo Group PLC
16 December 2021
 

Kanabo Group Plc

("Kanabo" or the "Company")

Materia Malta Commences First Sales of Medical Cannabis in Europe

 

Kanabo Group Plc (LSE:KNB), a medical cannabis and R&D Company that focuses on the distribution of cannabis-derived products for medical patients and wellness CBD consumers, notes that Materia's wholly-owned subsidiary Materia Malta Operating Ltd. ("Materia Malta") has commenced sales in Europe of the first medical cannabis flower produced at its EU GMP certified manufacturing site.

 

The inaugural product, named "Carbasi Verde", was released with a potency of 21.7% THC following successful completion of Materia Malta's first production cycle, which includes hand trimming to ensure the best quality for patients.

 

Carbasi Verde is now available at pharmacies across Malta, with subsequent shipments planned for Germany and the UK. The product has already been registered on the narcotics licence of Materia Deutschland GmbH ahead of its import into Germany.

 

As per the announcement on 4 November 2021, Kanabo Group Plc has finished the majority of its due diligence work as part of the proposed acquisition of the European businesses of 11157353 Canada Corp. (the "Proposed Transaction"), which trades under the name of Materia ("Materia"). Kanabo and Materia have therefore signed a revised term sheet which includes binding elements ("Head of Terms"), and the parties consider this to be an important step towards completion of the Proposed Transaction. As previously announced, the Proposed Transaction contemplates the full acquisition of Materia's European business, including its Maltese EU GMP certified facility, German medical cannabis wholesaler and UK CBD e-commerce platform. The Proposed Transaction is still subject inter alia to the agreement of formal documentation and conditional on, among other things, the receipt of all necessary regulatory consents.

 

 

"This journey began in earnest over two years ago, so we're elated to be offering patients Materia manufactured and branded medical cannabis," said Nick Pateras, Managing Director, Europe, of Materia. "Our Maltese site is truly state-of-the-art, and with our team's deep pharmaceuticals expertise we're confident that Materia Malta will become one of the most important production facilities in Europe's cannabis supply chain."

 

Avihu Tamir, CEO of Kanabo Group Plc said; "Materia's pace of progress remains remarkable. Subject to completion of the merger, the facility in Malta will enable Kanabo's enlarged group to broaden its distribution across Europe and solidify our plan for a complete supply and distribution line."

 

 

 

For further information, please visit http://www.kanabogroup.com or contact the following:

Kanabo Group Plc

Avihu Tamir, CEO

Via Vox Markets

Peterhouse Capital Ltd

Eran Zucker (Financial Adviser)

Tel: +44 (0)20 7469 0930

Lucy Williams / Charles Goodfellow (Corporate Broker)

Tel: +44 (0)20 7469 0930

Vox Markets (Investor Relations)

Kat Perez

KanaboGroup@voxmarkets.co.uk

 

 

About Kanabo Group Plc

Kanabo Group Plc is a medical cannabis and R&D company currently selling a range of wellness CBD Products across its Primary Markets and developing a range of and Medical Cannabis Products. The company's core strategy is to increase revenues from the sale of its Retail CBD Products in the wellness sector and to grow the Kanabo brand through its marketing initiatives. Learn more at https://www.voxmarkets.co.uk/listings/LON/KNB

 

About Materia

Materia's medicinal cannabis assets include its Maltese, German, and UK subsidiaries "Materia Malta", "Materia Germany", and "Materia UK" respectively. Materia Malta operates a European Union Good Manufacturing Practices ("EU GMP") certified facility, through which Materia Malta is able to import cannabis flower from its global supply network of cultivators and process it into EU GMP certified medical cannabis products. The Company anticipates that Materia Malta will be particularly well placed to process any new extracts developed by Kanabo. Materia Germany is a fully operational pharmaceutical wholesaler, with EU GDP and EU GMP certificates, enabling it to import and sell medical cannabis products directly to thousands of German pharmacies. Materia UK sells several leading CBD and wellness brands through Handpicked CBD, which aims to be one of the UK's largest CBD e-commerce marketplaces, and which now features Kanabo's own CBD line, as announced on 22 September 2021.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUVVSRASUUAAA
Date   Source Headline
2nd Dec 20222:59 pmRNSResignation of Auditor
15th Nov 20227:30 amRNSUpdate re: Investment into Hellenic Dynamics
24th Oct 20227:00 amRNSKanabo appointed to BSI Steering Group Committee
30th Sep 20227:01 amRNSInvestor Webinar hosted by Vox Markets
30th Sep 20227:00 amRNSHalf-year Report
30th Aug 20222:37 pmRNSGrant of Options
19th Aug 20225:30 pmRNSAppointment of Auditor
17th Aug 20222:05 pmRNSSecond Price Monitoring Extn
17th Aug 20222:00 pmRNSPrice Monitoring Extension
3rd Aug 20229:05 amRNSSecond Price Monitoring Extn
3rd Aug 20229:00 amRNSPrice Monitoring Extension
30th Jun 20225:02 pmRNSResult of AGM
30th Jun 20223:29 pmRNSAGM Statement
16th Jun 20227:00 amRNSNew Subsidiary
9th Jun 20227:00 amRNSContract Extension
8th Jun 20221:00 pmRNSNotice of AGM
6th Jun 20227:00 amRNSFinal Results
20th May 20227:00 amRNSUpdate on the Acquisition of Materia
3rd May 20227:00 amRNSTotal Voting Rights
19th Apr 20223:00 pmRNSExercise of Options and Total Voting Rights
22nd Mar 20227:00 amRNSBoard Changes
11th Mar 202211:23 amRNSInvestor Updates
9th Mar 20227:00 amRNSMoU with Forbe Ltd
1st Mar 20222:05 pmRNSSecond Price Monitoring Extn
1st Mar 20222:00 pmRNSPrice Monitoring Extension
28th Feb 20222:00 pmRNSTotal Voting Rights
25th Feb 20227:00 amRNSDirector/PDMR Dealing
23rd Feb 20227:00 amRNSBlock listing Interim Review
22nd Feb 20229:05 amRNSSecond Price Monitoring Extn
22nd Feb 20229:00 amRNSPrice Monitoring Extension
22nd Feb 20227:00 amRNSCompany Webinar
21st Feb 20225:30 pmRNSExercise of Put Option
21st Feb 20225:15 pmRNSOversubscribed Placing to Raise £2.25m
21st Feb 20224:54 pmRNSAcquisition of GP Service Ltd
31st Jan 202211:00 amRNSTotal Voting Rights
18th Jan 20227:00 amRNSMateria Announces Trading Update for 4Q22
6th Jan 20224:41 pmRNSSecond Price Monitoring Extn
6th Jan 20224:36 pmRNSPrice Monitoring Extension
31st Dec 202111:41 amRNSTotal Voting Rights
31st Dec 202110:00 amRNSGrant of Options
30th Dec 20211:00 pmRNSAchievement of Milestones
16th Dec 20217:05 amRNSMateria Malta First Sales in Europe
15th Dec 20217:00 amRNSPatent Advancement
7th Dec 20217:00 amRNSSubmission for Bioavailability and Efficacy Trial
6th Dec 20213:45 pmRNSExercise of Options
6th Dec 20217:00 amRNSUK Moves to License e-cigarettes and vaporizers
30th Nov 20214:02 pmRNSTotal Voting Rights
29th Nov 202111:05 amRNSSecond Price Monitoring Extn
29th Nov 202111:00 amRNSPrice Monitoring Extension
26th Nov 202111:57 amRNSKanabo to present at Mello: 29 November 2021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.